Dronedarone Hydrochloride and Optipranolol
Determining the interaction of Dronedarone Hydrochloride and Optipranolol and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Dronedarone can increase the blood levels and effects of metipranolol ophthalmic. In addition, combining these medications can increase the risk of an excessively slow heartbeat. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek immediate medical attention if you experience an irregular or slow heartbeat, fainting, chest pain, or difficulty breathing during treatment with these medications. Avoid driving or operating hazardous machinery until you know how the medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with dronedarone may increase the plasma concentrations of some beta-blockers. The mechanism is dronedarone inhibition of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers like metoprolol and propranolol. According to the product labeling, dronedarone increased metoprolol systemic exposure (AUC) by 1.6-fold and propranolol AUC by 1.3-fold. Pharmacodynamically, beta-blockers can potentiate the depressant effects of dronedarone on the sinus and AV nodes. In clinical trials, bradycardia was more frequently observed when dronedarone was given in combination with beta-blockers.
MANAGEMENT: Caution is advised if dronedarone is coadministered with a beta-blocker, including ophthalmic formulations. The dosage of the beta-blocker should start low and increased only after ECG verification of good tolerability. Patients should be advised to promptly report potential symptoms of toxicity such as excessive fatigue, fainting, difficulty breathing, chest pain or tightness, bradycardia, or arrhythmia.
- "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ.
Generic Name: dronedarone
Brand name: Multaq
Synonyms: Dronedarone
Generic Name: metipranolol ophthalmic
Brand name:
Synonyms: Optipranolol (Ophthalmic), OptiPranolol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dronedarone Hydrochloride-Optiray
- Dronedarone Hydrochloride-Optiray 160
- Dronedarone Hydrochloride-Optiray 240
- Dronedarone Hydrochloride-Optiray 300
- Dronedarone Hydrochloride-Optiray 320
- Dronedarone Hydrochloride-Optiray 350
- Optipranolol-Droperidol
- Optipranolol-Droperidol Injection
- Optipranolol-Drospirenone
- Optipranolol-Drospirenone and estradiol
- Optipranolol-Drospirenone and ethinyl estradiol
- Optipranolol-Drospirenone, ethinyl estradiol, and levomefolate